Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Official Title

Pre-Approval Access Single Patient Request Treatment for Talquetamab for Treating Physician Use in Relapsed or Refractory Multiple Myeloma

Brief Summary

The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.

Status

Available

EA Type

Individual Patients

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

Drug: Talquetamab
Talquetamab will be administered subcutaneously (SC).
Other Name: JNJ-64407564

Eligibility Gender

All

Eligibility Age

Minimum: 18 Years

Countries

Austria

Denmark

Finland

Greece

Netherlands

Switzerland

Contacts

Study Contact
844-434-4210
Participate-In-This-Study@its.jnj.com

Investigators

Janssen Research & Development, LLC Clinical Trial
Study Director
Janssen Research & Development, LLC

NCT Number

NCT05503550

MeSH Terms

Multiple Myeloma

Neoplasms, Plasma Cell

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA